Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Feb;41(2):478–480. doi: 10.1128/aac.41.2.478

Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.

K S Thomson 1, S A Chartrand 1, C C Sanders 1, S L Block 1
PMCID: PMC163735  PMID: 9021213

Abstract

An in vitro study of the activity of 15 antibacterial agents against 202 recent pediatric isolates of Streptococcus pneumoniae from urban and rural Nebraska and rural Kentucky identified trovafloxacin, ofloxacin, clindamycin, and vancomycin as the most active agents and equally active against both penicillin-susceptible and--resistant strains. In contrast, six beta-lactams, three macrolides, and trimethoprim-sulfamethoxazole were less active overall, especially against penicillin-intermediate and--resistant strains. Trovafloxacin inhibited all strains at a concentration of < or = 0.25 micrograms/ml and was 8- to 16-fold more potent than ofloxacin or ciprofloxacin.

Full Text

The Full Text of this article is available as a PDF (178.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Appelbaum P. C. New prospects for antibacterial agents against multidrug-resistant pneumococci. Microb Drug Resist. 1995 Spring;1(1):43–48. doi: 10.1089/mdr.1995.1.43. [DOI] [PubMed] [Google Scholar]
  2. Barry A. L., Pfaller M. A., Fuchs P. C., Packer R. R. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993. Antimicrob Agents Chemother. 1994 Oct;38(10):2419–2425. doi: 10.1128/aac.38.10.2419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Boken D. J., Chartrand S. A., Goering R. V., Kruger R., Harrison C. J. Colonization with penicillin-resistant Streptococcus pneumoniae in a child-care center. Pediatr Infect Dis J. 1995 Oct;14(10):879–884. doi: 10.1097/00006454-199510000-00012. [DOI] [PubMed] [Google Scholar]
  4. Doern G. V., Brueggemann A., Holley H. P., Jr, Rauch A. M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996 May;40(5):1208–1213. doi: 10.1128/aac.40.5.1208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Klugman K. P., Koornhof H. J. Drug resistance patterns and serogroups or serotypes of pneumococcal isolates from cerebrospinal fluid or blood, 1979-1986. J Infect Dis. 1988 Nov;158(5):956–964. doi: 10.1093/infdis/158.5.956. [DOI] [PubMed] [Google Scholar]
  6. Klugman K., Wasas A. In-vitro activity of the fluoroquinolone trovafloxacin against penicillin-susceptible and -resistant Streptococcus pneumoniae. J Antimicrob Chemother. 1995 Nov;36(5):873–874. doi: 10.1093/jac/36.5.873. [DOI] [PubMed] [Google Scholar]
  7. Liñares J., Pallares R., Alonso T., Perez J. L., Ayats J., Gudiol F., Viladrich P. F., Martin R. Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979-1990). Clin Infect Dis. 1992 Jul;15(1):99–105. doi: 10.1093/clinids/15.1.99. [DOI] [PubMed] [Google Scholar]
  8. Mason E. O., Jr, Kaplan S. L., Lamberth L. B., Tillman J. Increased rate of isolation of penicillin-resistant Streptococcus pneumoniae in a children's hospital and in vitro susceptibilities to antibiotics of potential therapeutic use. Antimicrob Agents Chemother. 1992 Aug;36(8):1703–1707. doi: 10.1128/aac.36.8.1703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Mason E. O., Lamberth L., Lichenstein R., Kaplan S. L. Distribution of Streptococcus pneumoniae resistant to penicillin in the USA and in-vitro susceptibility to selected oral antibiotics. J Antimicrob Chemother. 1995 Dec;36(6):1043–1048. doi: 10.1093/jac/36.6.1043. [DOI] [PubMed] [Google Scholar]
  10. Nelson C. T., Mason E. O., Jr, Kaplan S. L. Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment. Pediatr Infect Dis J. 1994 Jul;13(7):585–589. doi: 10.1097/00006454-199407000-00001. [DOI] [PubMed] [Google Scholar]
  11. Pankuch G. A., Jacobs M. R., Appelbaum P. C. Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother. 1995 Jan;35(1):230–232. doi: 10.1093/jac/35.1.230. [DOI] [PubMed] [Google Scholar]
  12. Pankuch G. A., Jacobs M. R., Appelbaum P. C. Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone. Antimicrob Agents Chemother. 1994 Dec;38(12):2905–2907. doi: 10.1128/aac.38.12.2905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Spangler S. K., Jacobs M. R., Appelbaum P. C. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother. 1994 Apr;38(4):898–900. doi: 10.1128/aac.38.4.898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Spangler S. K., Jacobs M. R., Appelbaum P. C. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother. 1992 Apr;36(4):856–859. doi: 10.1128/aac.36.4.856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Steele R. W., Warrier R., Unkel P. J., Foch B. J., Howes R. F., Shah S., Williams K., Moore S., Jue S. J. Colonization with antibiotic-resistant Streptococcus pneumoniae in children with sickle cell disease. J Pediatr. 1996 Apr;128(4):531–535. doi: 10.1016/s0022-3476(96)70365-7. [DOI] [PubMed] [Google Scholar]
  16. Tateda K., Takashima K., Miyazaki H., Matsumoto T., Hatori T., Yamaguchi K. Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model. Antimicrob Agents Chemother. 1996 Jun;40(6):1520–1525. doi: 10.1128/aac.40.6.1520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Thomson K. S., Sanders W. E., Sanders C. C. USA resistance patterns among UTI pathogens. J Antimicrob Chemother. 1994 May;33 (Suppl A):9–15. doi: 10.1093/jac/33.suppl_a.9. [DOI] [PubMed] [Google Scholar]
  18. Visalli M. A., Jacobs M. R., Appelbaum P. C. Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology. J Antimicrob Chemother. 1996 Jan;37(1):77–84. doi: 10.1093/jac/37.1.77. [DOI] [PubMed] [Google Scholar]
  19. Visalli M. A., Jacobs M. R., Appelbaum P. C. MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother. 1996 Feb;40(2):362–366. doi: 10.1128/aac.40.2.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Yee Y. C., Thornsberry C., Brown S. D., Bouchillon S. K., Marler J. K., Rich T. A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 1993 Nov;32 (Suppl B):13–19. doi: 10.1093/jac/32.suppl_b.13. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES